STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersDemocrats are likely to focus on reversing Medicaid cuts and expanding insurance coverage, giving a boost to health care providers.
By Chella·11m ago
Why it mattersPithy intro text about the biopharma milieu.  Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene th…
By Chella·2h ago
Why it mattersNovartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy
By Chella·3h ago
Why it mattersThe explosive court battle between a former star scientist at the Massachusetts Institute of Technology and a younger colleague continues to roil the campus community.
By Chella·23h ago